Public hearing on CBD regulation held in the US
As CBD continues to rapidly expand globally, the U.S. Food and Drug Administration will hold its first public hearing concerning the regulation of cannabis and cannabis-derived compounds on Friday May 31st. The results will certainly be worth bearing in mind when you buy CBD.
The legal status of CBD oils
CBD, or cannabidiol, is one of over 100 different cannabinoids found within plans from the Cannabis genus. The most famous cannabinoid is THC, which is the compound that induces the psychoactive effects (the high) typically associated with Cannabis. On the other hand, CBD has no psychotropic qualities.
CBD products are currently legal in the U.S. so long as they’re derived from hemp, and the extract used contains under 0.3% THC. That's why we ensure our CBD oral oils and CBD cosmetics contain 0% THC.
A CBD statement from the FDA
In a statement by Scott Gottlieb announcing the hearings back in April, the FDA outlined their stance on why the conversation around CBD is so important:
Stakeholders are looking to the FDA for clarity on how our authorities apply to such [CBD] products, what pathways are available to market such products lawfully under these authorities, and how the FDA is carrying out its responsibility to protect public health and safety with respect to such products.
What’s clear is that the FDA recognises there is a convergence of interest on CBD from several different sectors, including the pharmaceutical industry, potential consumers and users, and the CBD-specific companies that have emerged in the past few years. By opening up this debate to a public hearing, the FDA is making a strong statement about the future of CBD products.
Accordingly, Gottlieb's statement also clarified the nature of the public hearing, and why it’s a communal conversation rather than a one-sided one:
The public hearing will give stakeholders an opportunity to provide the FDA with additional input relevant to the agency’s regulatory strategy related to existing products, as well as the lawful pathways by which appropriate products containing cannabis or cannabis-derived compounds can be marketed, and how we can make these legal pathways more predictable and efficient.
The big question at the heart of this hearing, however, is concerning the distinction between high quality CBD products, and the array of other CBD oils on the market, particularly food and drinks infused with cannabidiol:
There are open questions about whether some threshold level of CBD could be allowed in foods without undermining the drug approval process.
The implication is that by providing different CBD limits for higher quality CBD products, and those available in food and drinks, both can be regulated more easily, whilst also giving a further incentive to companies to invest time and money into researching CBD.
This regulation also extends to firms marketing the therapeutic nature of CBD, and its potential effects. Much like in the UK, unsubstantiated claims can’t be made about CBD products, and yet because the marketplace is so saturated many companies are taking advantage of the situation.
At Vitality CBD we agree wholeheartedly with this stance, which is why you won’t find any medical claims made anywhere on our website. The continued safety of CBD users should be the number one priority for any CBD company currently in the marketplace.
What the resulting impact of the hearing on Friday will be remains to be seen, but it’s telling that such large scale conversations about CBD are being held at a national level in America. We’ll have all the latest industry news to keep you informed right here at Vitality.
Learn more about CBD
If you're new to the world of CBD and have questions that weren't resolved here, check out our 4-step CBD guide. For anything else, our experienced team are always on hand to field any questions. Reach out to us on our contact page. We always want you to feel confident buying CBD with us.